MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...
Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination ...
Microsoft faces intensifying competition from Alphabet/Google, as both companies' AI and cloud strategies increasingly ...
Alphabet Inc. has successfully converted AI from a threat to an additive opportunity to its existing moat. Learn more about ...
Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...
First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...
TipRanks on MSN
Candel Therapeutics hosts virtual R&D day on immunotherapy
An announcement from Candel Therapeutics ( ($CADL) ) is now available. On December 5, 2025, Candel Therapeutics will host a virtual R&D Day to ...
An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group Limited has announced that its GLP-1/GIP ...
Continuous variable modeling such as the Hodgkin lymphoma international prognostic index (A-HIPI) improves prognostic ...
Key market opportunities include strategic investment decisions informed by global clinical trial analysis, identification of optimal trial locations to minimize costs, recognition of prominent drugs ...
On 12 November 2025, Bristol-Myers Squibb conducted a Phase 3 study to Evaluate the Efficacy and Safety of KarXT + KarX-EC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback